密固达抗骨质疏松治疗对患者生活质量的影响分析  

Effects of zoledronic acid on quality of life in patients with osteoporosis

作　　者：丘惠嫦[1] 楼慧玲[1] 陈巧聪[1] 饶红英[1] 

机构地区：[1]广州医学院附属广州市第一人民医院老年病科,广东广州510180

出　　处：《广州医学院学报》2013年第2期47-49,共3页Academic Journal of Guangzhou Medical College

基　　金：广东省科技计划项目(2009B030801051)

摘　　要：目的:观察并分析密固达抗骨质疏松治疗对改善患者生活质量的临床效果。方法:选取本院2009年6月至2011年6月236例骨质疏松的患者,给予密固达治疗,并应用骨质疏松症评估问卷(OPAQ2)和简明健康生活量表(SF-36)对患者治疗前后进行生活质量的评估。结果:经密固达治疗后,患者的OPAQ和SF-36得分有显著升高,P<0.05。结论:经密固达抗抗骨质疏松治疗后,患者的生活质量得到明显改善,具有临床应用价值。Objective： To assess the efficacy of zoledronic acid on the quality of life in patients with osteoporosis. Methods： We recruited 236 patients with osteoporosis who were treated with zoledrnnic acid between June 2009 and .June 2011. The questionnaire （ OPAQ2 ） and concise heahh life scale （SF-36） were assessed prior to and after the treatment. Results： Treatment with zoleronic acid yielded a substantial improvement in OPAQ and SF-36 scores in patients with osteoporosis （both P 〈0.05）. Conclusion： Treatment with zoledronic acid is associated with considerably improved quality of life patients with osteoporosis and is of clinical significance for application.

关 键 词：骨质疏松 生活质量 OPAQ2 SF-36 

分 类 号：R634[医药卫生—外科学]